Latest Breaking News On - Biomedicines inc - Page 2 : comparemela.com

Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)

Endeavor BioMedicines Enters License Agreement with Hummingbird Bioscience for Worldwide Rights to HMBD-501, a Next Generation HER3-Targeted Antibody-Drug Conjugate (ADC)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

John hoodBiomedicines incHummingbird bioscienceNew drugEndeavor biomedicinesHummingbird bioPiers ingram

Intarcia s diabetes drug-device combo voted down again by FDA panel

BioPharma

David cookeDrug administrationBiomedicines incMerck coMelinda gates foundationIntarcia therapeutic typeFlow wangMelinda gates

TRIANA Biomedicines to Present at UBS Biotechnology Private Company Virtual Symposium

TRIANA Biomedicines, Inc. (TRIANA), an innovative biopharmaceutical company focused on advancing a target-first and rational molecular glue discovery platform to address difficult to drug disease targets, today announced that Dr. Patrick Trojer, President and Chief Executive Officer, will present at the UBS Biotechnology Private Company Virtual Symposium on Wednesday September 20, 2023 at 3:30 PM ET.

United statesPatrick trojerBiotechnology private company virtual symposium on wednesdayBiomedicines incChief executive officerPrivate company virtual symposiumWednesday septemberIopharmaceutical companyRivate biotechnology companyDrug discoveryDisease targets

UBS Group AG (UBS) Shares Plummet Below 1-Year High

The stock price of UBS Group AG (NYSE: UBS) has plunged by -0.08 when compared to previous closing price of 26.02, but the company has seen a 1.48% gain in its stock price over the last five trading sessions. Accesswire reported 2023-09-18 that LEXINGTON, MA / ACCESSWIRE / September 18, 2023 / TRIAN

United statesPatrick trojerBiomedicines incBiotechnology private company virtual symposium on wednesdayChief executive officerPrivate company virtual symposiumWednesday septemberDay movingNyse ubsUbs group agEbs stock

Flagship-backed Generate Bio pulls in $273M, one of 2023 s top VC rounds

With one program in the clinic and another not far behind, Generate Biomedicines Inc. raised $273 million in a series C financing to advance its generative biology platform. It is one of the largest venture capital (VC) rounds for a U.S. company in 2023. Funds will go toward advancing the Somerville, Mass.-based company’s 17 pipeline programs, including the filing of multiple IND applications in 2024.

Biomedicines incGenerate biomedicinesGenerate biomedicines incVenture capitalArtificial intelligenceMachine learningDrug discovery